E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoadjuvant Therapy in Rectal Cancer
Conditions
Neoadjuvant Therapy in Rectal Cancer
Trial Timeline
May 17, 2017 → Sep 30, 2021
NCT ID
NCT03152370About E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6) is a phase 1 stage product being developed by Adlai Nortye for Neoadjuvant Therapy in Rectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03152370. Target conditions include Neoadjuvant Therapy in Rectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03152370 | Phase 1 | Completed |
Competing Products
4 competing products in Neoadjuvant Therapy in Rectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Trastuzumab Emtansine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib | Pfizer | Phase 2 | 51 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| Pembrolizumab, Eftilagimod alfa | Immutep | Phase 2 | 44 |